key: cord-0864284-4xmrqbq5
authors: Yazıcı, O.; Ünsal, O.; Özdemir, N.; Çubukçu, E.; Ocak, B.; Üner, A.; Özet, A.
title: 1568P Clinical and laboratory outcomes of solid cancer patients reinfected with SARS-CoV-2
date: 2021-09-30
journal: Annals of Oncology
DOI: 10.1016/j.annonc.2021.08.1561
sha: 785e4e2f9cc3a6bc21860b4d0366b6fead17c726
doc_id: 864284
cord_uid: 4xmrqbq5

Background: COVID-19 reinfection has been increasingly reported. Immunocompromised patients may be more susceptible to COVID-19 reinfection due to impaired immune responses to the virus. The current study aimed to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients with a diagnosis of solid cancer and COVID-19 PCR positive were screened. The patients enrolled whether patient has at least one negative COVID-19 PCR test and clinical improvement. In addition to that at least 28 days after the previous positive COVID-19 PCR result, the patient must have a confirmed COVID-19 PCR positive result again. Results: Total 1024 patients with COVID-19 PCR positive solid malignancy were screened. Thirty-two patients were included in the study. The median time between the first COVID-19 infection and reinfection was 46 (30-194) days. The reinfection rate was 3.1%. The most common cancer subtype was lung cancer. Mortality rate of reinfection was 34.3% (n=11). Ferritin and creatinine values of serum parameters in reinfection were found to be significantly higher compared to the first infection, respectively (p:0.015, p:0.014). Nine patients with only 1 comorbidity had higher mortality (p=0.052). During reinfection period rate of patients hospitalized in intensive care unit was significantly higher compared with rate of patients during first COVÍD-19 infection (p:0.002). The mortality rate in 8 patients using antiaggregant or anticoagulant for a long time was not statistically different from the group who did not use it (p:0.681). Conclusions: Solid cancer patients have a higher mortality rate in COVID-19 reinfection. The reinfection rate was 3.1%. This study demonstrated one of the first preliminary clinical results of COVID-19 reinfection in solid cancer patients. Legal entity responsible for the study: Oktay Ünsal. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

Background: At the height of the first wave of the SARS-COV-2 pandemic, ESMO mobilized to accelerate research for the understanding of COVID-19 in cancer patients (pts). ESMO CoCARE is an international collaborative registry-based, cohort study, gathering real-world data and information from healthcare professionals about the natural history, treatment and outcomes of COVID-19 in cancer pts.

Methods: ESMO CoCARE captures information on pts with any solid or hematologic malignancy (including cancer survivors free of disease for 5 years) presenting with a COVID-19 diagnosis in any of the participating centers. Data collected since 06/2020 include demographics, cancer characteristics and status, co-morbidities, COVID-19 clinical features, course, management and outcome. Factors influencing COVID-19 severity (hospitalization +/-ICU support needed) and recovery are investigated using multivariable logistic regression with backward elimination method. The study is ongoing.

Results: The current analysis includes 1551 registered pts (19 countries; 87% pts from 23 European centers, 7% and 6% pts from 5 Northern African and 7 Asian centers), with COVID-19 diagnosis as of 11/03/2021. Median age was 64 years, with the majority female (52%), cancer stage III/IV (58%), and on active cancer treatment (60%). 65% had severe COVID-19 requiring hospitalization, with 11% receiving intensive care. In multivariable analysis, in addition to demographics (male gender, older age, other ethnicity than Caucasian, lower BMI), co-morbidities and symptomatic COVID-19, severe disease was associated to higher ECOG PS (Odds Ratio (OR) 2 vs 0 ¼5.9, OR 1 vs 0 ¼2.1), hematological malignancies (OR hemvs solid ¼2.0), and active/ progressive cancer status (OR progressivevs no evidence of disease ¼1.6). 98% of pts with mild disease recovered, as opposed to only 70% of those with severe disease. Cancer stage was an additional prognostic factor for recovery (OR I/II vs IV ¼3.4).

Conclusions: Demographic characteristics, type and status of cancer, and symptomatology of COVID-19 increase the probability of severe disease, while advanced cancer stage is also associated with the risk of death.

Legal entity responsible for the study: Institut Curie, Paris, France. -194) days. The reinfection rate was 3.1%. The most common cancer subtype was lung cancer. Mortality rate of reinfection was 34.3% (n¼11). Ferritin and creatinine values of serum parameters in reinfection were found to be significantly higher compared to the first infection, respectively (p:0.015, p:0.014). Nine patients with only 1 comorbidity had higher mortality (p¼0.052). During reinfection period rate of patients hospitalized in intensive care unit was significantly higher compared with rate of patients during first COV _ ID-19 infection (p:0.002). The mortality rate in 8 patients using antiaggregant or anticoagulant for a long time was not statistically different from the group who did not use it (p:0.681).

Conclusions: Solid cancer patients have a higher mortality rate in COVID-19 reinfection. The reinfection rate was 3.1%. This study demonstrated one of the first preliminary clinical results of COVID-19 reinfection in solid cancer patients.

Legal entity responsible for the study: Oktay Ünsal.

Funding: Has not received any funding. Background: SARS-CoV-2 infection can induce a host hyperinflammatory response induced by a cytokine storm, that is the main cause of mortality. Myelosuppression is associated with higher risk of infections and mortality. Few reports have addressed about the management of patients with neutropenia and COVID-19. Herein, we present a retrospective study during COVID-19 outbreak in neutropenic cancer patients with COVID-19 comparing the outcome and survival between G-CSF treated vs G-CSF non-treated group.

Methods: Retrospective data were collected from clinical reports. Inclusion criteria were cancer with neutropenia (<1500 cells/mm3) and concomitant COVID-19 infection. Comorbidities, tumor, stage, treatment, neutropenia severity, G-CSF, COVID-19 parameters and mortality were analyzed. Exploratory analysis of both cohorts (G-CSF treated and G-CSF non treated) and a multivariable logistic regression was done to predict respiratory failure and death.

Results: Among 943 patients with cancer and COVID-19 from14 hospitals in Spain, 8% had neutropenia. Two cohorts according to G-CSF treatment were identified: 40 patients received G-CSF vs 43 G-CSF non-treated. Lung (26%) was the main location and most had advanced disease (67%). No differences according to baseline characteristics were found, except for the cancer treatment and the center s protocols for neutropenia management (p¼0,001). 63% of patients died because respiratory failure. Neumonia was presented in 76% of patients. Patients treated with G-CSF had a higher rate of respiratory failure vs non-treated (p¼0.001) and required oxygen support (p¼0.002). In G-CSF treated cohort, we found that the days with G-CSF showed a significant trend toward worse outcome and higher mortality. A logistic regression model was developed to predict respiratory failure as a function of the days of G-CSF treatment. After adjusting several relevant covariates, a significant effect was obtained for the days of G-CSF treatment (OR ¼ 1.4, 95% CI [1.03, 1.92], p-value ¼ 0.01).

Conclusions: Our findings suggest that G-CSF treatment could be disadvantageous in cancer patients with COVID-19, with a probable worse outcome.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding.

Disclosure: All authors have declared no conflicts of interest. https://doi.org/10.1016/j.annonc.2021.08.1562

Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20

Testing recommendations were set by the Federal Office of Public Health. The main objective of the study was to assess the outcome (i.e. mortality, rate of hospitalization, ICU admission) of COVID-19 infection in cancer patients, the main secondary objective was to define prognostic factors. Results: With a cutoff date of March 15, 2021 and exclusion of 46 patients who refused consent, 455 patients were included into the final analysis. Most frequent malignancies were breast in 63 cases (14%), lung in 47 (10%), prostate cancer in 25 (6%), myeloma in 19 (4%); 205 patients (45%) had non-curative disease. Systemic treatment within 3 months prior to COVID-19 diagnosis included chemotherapy in 101 cases (23%), targeted therapy in 94 (21%), steroids in 78 (17%) and checkpoint inhibitors in 34 (8%). 285 patients (63%) were hospitalized for COVID-19, 213 (47%) required oxygen, 43 (9%) invasive ventilation, 62 (14%) were admitted to the ICU. Death from COVID-19 infection occurred in 98 patients, resulting in a mortality rate of 21.5%. Age 65 versus <65 (OR 3.35, p¼0.001), non-curative versus curative disease (OR 2.21, p¼0.021), ICU admission (OR 4.53, p <0.001) and oxygen requirement (OR 23.25, p <0.001) were independently associated with increased mortality. Neither male versus female gender

Legal entity responsible for the study: Swiss Clinical Cancer Research Group (SAKK)

Funding: The study was financially supported by Roche and by research agreements with the following institutions: Swiss State Secretary for Education, Research and Innovation (SERI), Swiss Cancer Research Foundation (SCS) and Swiss Cancer League (SCL)

Clinical trial activity: AstraZeneca; Financial Interests, Institutional, Invited Speaker

Clinical study activity: Immunophotonics; Financial Interests, Institutional, Invited Speaker, Clinical study activity: Innomedica; Financial Interests, Institutional, Invited Speaker, Clinical study activity: MSD; Financial Interests, Institutional, Invited Speaker

Advisory Role: BMS; Non-Financial Interests, Advisory Role: Debiopharm; Non-Financial Interests, Advisory Role: MSD; Non-Financial Interests, Advisory Role: Roche; Non-Financial Interests, Advisory Role: Sanofi. K. Zaman: Financial Interests, Institutional, Advisory Board: Daiichi; Financial Interests, Institutional, Advisory Board: Lilly; Financial Interests, Institutional, Advisory Board: MSD Oncology; Financial Interests, Institutional, Advisory Board: Mylan

Advisory Board: Pierre Fabre; Financial Interests